Objectives: Diagnosis of B-cell acute lymphoblastic leukemia (B-ALL) requires immunophenotypic evidence of B-lineage and absence of specific myeloid or T-lineage markers. Rare cases of otherwise typical B-ALL express myeloperoxidase (MPO) detectable by flow cytometry with an absence of other myeloid markers, but the clinical significance of this finding is not well studied.
Results: Twenty-nine cases of otherwise typical B-ALL that expressed MPO by flow cytometry (B-ALLisoMPO) without expression of other myeloid markers were identified. The B-ALL-isoMPO group had a significantly increased incidence of relapse (univariate log rank P ¼ .0083; multivariate hazard ratio, 2.50; 95% confidence interval, 1.07-5.85; P ¼ .034) and significantly worse event-free survival by univariate analysis (log rank P ¼ .0066) compared with a reference group of patients with B-ALL from the same time period (n ¼ 264).
Conclusions: To our knowledge, this is the first report to document the clinical outcomes in a group of pediatric patients with B-ALL that expresses MPO in the absence of other myeloid markers. This group had an increased rate of relapse and a worse event-free survival than the patients with B-ALL who did not express MPO.
Appropriate classification of acute leukemia in newly diagnosed patients is essential for determination of the appropriate risk-adjusted treatment regimen. The World Health Organization Classification of Tumors of Hematopoietic and Lymphoid Tissues (2008 WHO) defines the diagnosis of B-cell acute lymphoblastic leukemia (B-ALL) based on immunophenotypic evidence of early B-lymphoid differentiation. 1 However, when this occurs with significant myeloid or T-antigen coexpression, a more complex phylogeny becomes evident, and 2008 WHO classifies this as mixed-phenotype acute leukemia (MPAL). This classification scheme is not revised significantly in the 2016 WHO update. 2 The expression of myeloperoxidase (MPO) is recognized as a specific marker of myeloid lineage and is therefore considered definitive evidence of myeloid differentiation. Typically, MPO is accompanied by additional evidence of myeloid differentiation. 2 Factors predictive of outcome in B-ALL include age, WBC, karyotype, and postinduction assessment of minimal residual disease levels. Whether these clinical and laboratory features are also predictive in patients diagnosed with MPAL remains to be determined. Rarely, immunophenotypic analysis of an otherwise typical B-ALL identifies MPO expression alone without any other typical myeloid lineage markers. While technically fulfilling the 2008 WHO criteria for MPAL (B/myeloid), diagnosticians have been reluctant to categorize these cases as such and, in the absence of other characteristic cytogenetic abnormalities, suggest caution in rendering a diagnosis of MPAL. [2] [3] [4] Investigation of the clinical significance of isolated MPO expression and thus the appropriate classification of this rare acute leukemia is critical for directing appropriate therapy. Cases of acute lymphoblastic leukemia with MPO expression in the absence of other myeloid lineage marker expression have also been reported previously. 14, 21 However, these studies did not report patient outcomes with modern and more effective chemotherapy regimens. This report represents a retrospective analysis of all new leukemias diagnosed at our institution to evaluate (1) the frequency of flow cytometry-determined isolated MPO expression in otherwise typical B-ALL, (2) the rate of concordance of flow cytometry-defined MPO positivity with cytochemistry and immunohistochemistry, and (3) clinical outcomes of patients with B-ALL that expressed MPO by flow cytometry (B-ALL-isoMPO) compared with B-ALL and MPAL (B/ myeloid). Outcomes in this study were measured by cumulative incidence of relapse (CIR), event-free survival (EFS), and overall survival (OS). This analysis suggests that B-ALL-isoMPO represents a group of patients with a higher risk of relapse than those with B-ALL.
Materials and Methods

Study Cohort
Children, adolescents, and young adults 1 to 20 years of age diagnosed with B-ALL or MPAL, B/myeloid at Children's Hospital Los Angeles (CHLA) between 2008 and 2015 were included in the study. Three populations were identified: B-ALL as a reference cohort, B-ALL with isolated MPO expression as described below (B-ALLisoMPO), and MPAL (B/myeloid only). B-ALL was defined using CD19 as a screening immunophenotype marker, plus additional immunophenotypic evidence of B-lineage. To obtain a homogeneous B-ALL population as the reference group, we excluded cases with BCR-ABL translocations (n ¼ 8), MLL rearrangements (n ¼ 3), Down syndrome (n ¼ 11), hypodiploidy (n ¼ 1), and one case with t(5;14). The B-ALL-isoMPO group was defined as leukemia with MPO expression alone (ie, no other myeloid markers) in more than 20% on the blast population in an otherwise typical B-ALL. Cases that expressed myeloid or monocytic markers in addition to MPO expression was evaluated in all cases. MPO expression in the leukemic blasts was compared with the appropriate internal negative, isotype, and positive controls. We used the negative control with the highest upper limit in each case, with subjective alignment of the cursor to the upper edge of the negative population. Greater than 20% of the leukemic blasts showing intensity of MPO expression in excess of the upper limit of negative controls was considered positive.
Immunohistochemistry
Immunohistochemical analysis of MPO (clone 59A5; Leica Biosystems, Newcastle, UK) using the automated Bond system (Leica Biosystems) was performed in cases with available tissue material. Staining was interpreted as positive if present on lymphoblasts. Archival immunohistochemical stained specimens were reviewed in two cases.
Cytochemistry
Cytochemical evaluation was performed by standard techniques on a subset of cases identified as expressing MPO by flow cytometry. The blasts were classified as positive or negative using the French-American-British cutoff of at least 3% of the blasts positive for MPO expression. 6 
Statistical Analysis
The three groups of patients were compared with each other on the basis of sex and NCI/Rome risk category with Outcome data were assessed using survival analyses for CIR (time to first relapse following morphologic complete remission), EFS (defined as time to relapse or death), and OS. Kaplan-Meier analysis was used for univariate comparisons between the three groups of patients with CIR, EFS, and OS.
Individual Cox multiple regression models were built in a stepwise fashion for each outcome to assess the influence of isolated MPO expression in B-ALL after controlling for patients' clinical characteristics. Each model was first constructed to examine historical B-ALL predictors of survival with retention in the model of covariates significant at a level of .05. The additional effect of isolated MPO expression in B-ALL was then added to each of the resulting outcome-specific models. Nonadditive effects of isolated MPO expression in B-ALL were examined by including interaction terms to assess whether the isolated MPO effect on CIR, EFS, or OS depended on age or WBC. Sensitivity analysis was performed to reassess the effects of isolated MPO expression in B-ALL in the Cox multiple regression models by analyzing the effects by NCI/Rome risk category instead of continuous age and WBC variables. Permutation tests were used to validate whether the effect of isolated MPO expression in B-ALL on patients' relapse, OS, and EFS observed in the data was likely to have arisen by chance. All tests were two-sided with significance set at P < .05. Statistical computations were performed using Strata/IC 13.1 (StrataCorp, College Station, TX).
Results
Description of Cohort
Between 2008 and 2015, a total of 264 cases met criteria for standard B-ALL, 29 cases met criteria for B-ALLisoMPO, and 21 met criteria for MPAL, B/myeloid. Table 1 summarizes the myeloid antigen expression found in the three groups. The median follow-up of the patients with B-ALL, B-ALL-isoMPO, and MPAL was 40.2 months (range, 0.4-87.9 months), 47.3 months (range, 6.7-86.3 months), and 35.9 months (range, 0.8-66.6 months) respectively. Table 2 summarizes the distributions of clinical parameters among B-ALL, B-ALL-isoMPO, and MPAL patient groups. As shown in Table 2 , there are distribution differences in sex (v 2 P ¼ .001), age (Kruskal-Wallis P ¼ .0005), diagnosis (v 2 P < .0001), and karyotype (Fisher exact P ¼ .006) across B-ALL, B-ALLisoMPO, and MPAL patient groups. There were no MLL or BCR-ABL rearrangements in any of the cases.
Lack of Concordance Between Cytochemical, Immunohistochemical, and Flow Cytometric Evaluation of MPO Expression
Of all B-ALL and MPAL (B/Myeloid) leukemia cases diagnosed between 2008 and 2015, we identified 8.6% (29 of 338) with B-ALL and isolated MPO expression by flow cytometry. The mean 6 SD level of expression of MPO for the B-ALL, B-ALL-isoMPO, and MPAL groups was 2.4% 6 3.5%, 54.6% 6 22.6%, and 39.3% 6 21.0%, respectively Figure 1 . Immunohistochemical staining for MPO was performed on freshly cut tissue for 19 of 29 B-ALL-isoMPO cases and was reviewed on two of 29 cases that had archived MPOstained slides available. The remaining cases had insufficient tissue available. Of the 21 MPO-stained cases, only one (4.8%) showed partial positive staining of the lymphoblasts. Cytochemical staining was performed on 26 of the 29 B-ALLisoMPO cases, and only one (3.8%) was positive in at least 3% of lymphoblasts. The cytochemistry-positive case was not the same case that was immunohistochemistry (IHC) positive.
Flow Cytometric Patterns of MPO Expression in the B-ALL-isoMPO Cases
When the pattern of MPO expression in the B-ALLisoMPO cases is examined, three general patterns are noted. The first and most common pattern (seen in 20/29 cases) shows a tail of MPO expression extending from the lymphoblast population Figure 2A , Figure 2B , and Figure 2C . All nine cases of relapse showed this tailed MPO expression pattern. The second most common expression pattern was uniformly positive MPO expression in all of the blasts, seen in six of 29 cases Figure 2D , Figure 2E , and Figure 2F . The least common expression pattern was partial MPO expression, seen in three of 29 cases Figure 2G , Figure 2H , and Figure 2I . Figure 1 Average myeloperoxidase (MPO) expression of each patient cohort group by flow cytometry. The MPO expression of the lymphoblast population was determined for each de novo leukemia by comparing the lymphoblast population with both internal reference controls and isotype controls. The data are presented as the percentage of the lymphoblast population expressing MPO. Each MPO-positive case was reviewed by two independent flow cytometry experts. B-ALL, B-cell acute lymphoblastic leukemia; MPAL, mixed-phenotype acute leukemia.
CIR
Significant differences in the CIR were observed by univariate analyses among the B-ALL, B-ALL-isoMPO, and MPAL groups (log-rank P ¼ .0083; Figure 3 ). In a multivariate Cox regression model for CIR Table 3 , the B-ALLisoMPO group was associated with increased risk of relapse after adjustment for age, WBC, and sex (hazard ratio [HR], 2.50; 95% confidence interval [CI], 1.07-5.85; P ¼ .034). There was a trend for increased CIR in the MPAL group compared with B-ALL, but this did not reach the level of significance (HR, 2.68; 95% CI, 0.90-8.01; P ¼ .077). Age and WBC at diagnosis were associated with an increased CIR (P ¼ .012 and P < .0001, respectively), and analysis of the interaction terms showed there was a significant difference in relapse for the B-ALL-isoMPO group that depended on age (P ¼ .005) but not WBC (P ¼ .510). Sensitivity analysis using NCI/Rome criteria showed similar trends but did not reach the level of significance. Nonetheless, permutation tests from the model confirmed significant differences in relapse rates between the groups (P ¼ .0425).
EFS
A significant difference in EFS was present among the B-ALL, B-ALL-isoMPO, and MPAL (log-rank test P ¼ .0066) groups. Figure 4 represents Kaplan-Meier curves illustrating time to relapse or death by the three patient groups. Furthermore, there were significant differences in EFS between SR and HR (log-rank P < .0001) and across karyotype (log-rank P ¼ .0004). On the other hand, there was no significant different in EFS between females and males (log-rank P ¼ .8464). After adjusting for sex, age, and WBC, the B-ALLisoMPO group had worse EFS, but this did not reach significance in a multivariate Cox regression model (HR, 2.13; 95% CI, 0.92-4.90; P ¼ .077). In the same model, the MPAL group was significantly associated with higher relapse or death compared with B-ALL (HR, 2.89; 95% CI, 1.07-7.78; P ¼ .036) after adjusting for sex, age, and WBC Table 4 .
OS
There was no difference in survival among the B-ALL, B-ALL-isoMPO, and MPAL (P ¼ .6383) groups based on the log-rank test. Figure 5 shows Kaplan-Meier curves that illustrate time to death in the three patient groups. In addition, there were no differences in survival between females and males (log-rank P ¼ .7849; data not shown). However, there were significant differences in survival between SR and HR (log-rank P ¼ .0003; data not shown) and across karyotype (log-rank P ¼ .0007; data not shown).
Multivariate Cox regression modeling shows that the B-ALL-isoMPO group was not significantly associated with death (HR, 0.91; 95% CI, 0.23-3.66; P ¼ .893) after adjusting for sex, age, and WBC Table 5 . When compared with SR leukemia, however, HR leukemia was significantly associated with death after adjusting for patient groups and sex (HR, 9.57; 95% CI, 2.13-43.05; P ¼ .003; data not shown).
Discussion
We have assessed the clinical outcomes in three groups of patients with acute leukemia: patients with B-ALL who express MPO by flow cytometry in the absence of other myeloid lineage markers (B-ALL-isoMPO), patients with B-ALL, and patients with MPAL (B/myeloid). Compared with B-ALL with no myeloid antigen expression, patients with B-ALL with isolated MPO expression experience a significantly increased risk of relapse despite similar therapy. In addition, the B-ALL-isoMPO group tended to consist of older men (86.2% male) without common B-ALL-related karyotypic findings. With respect to CIR and EFS, our data suggest that the biological behavior of B-ALL-isoMPO cases is more similar to MPAL than B-ALL. Relapse remains the leading cause of acute lymphoblastic leukemia-related mortality 7 ; therefore, identification of B-ALL with MPO expression is important to guide appropriate therapy.
Greater than 3% MPO-positive cells by enzyme cytochemistry is the minimum threshold to establish myeloid lineage. 6 Such a threshold has not been formally Figure 3 Kaplan-Meier plot of the cumulative incidence of relapse (CIR). Univariate analysis of CIR shows a significantly higher incidence of relapse in patients with isolated myeloperoxidase expression in otherwise immunophenotypically standard B-cell acute lymphoblastic leukemia. *Log-rank P ¼ .0083. MPAL, mixed-phenotype acute leukemia. ranging from 13% to 28%. 11, 12 While arbitrary cutoff values likely do not accurately reflect the underlying biology of the leukemic process, thresholds are helpful for classification of ambiguous leukemias under the current classification system. The B-ALL-isoMPO immunophenotypic profile was observed in 8.6% of new B-ALL and MPAL (B/myeloid) diagnoses over the 7-year study period. We have observed that MPO expression by flow cytometry is poorly associated with concomitant MPO expression by immunohistochemistry or cytochemistry. Reliance on cytochemical and/or immunohistochemistry MPO evaluation may give a false negative due to sensitivity issues. Alternatively, given that the production of functional MPO enzyme is the result of a complex multistep synthesis with processing in the endoplasmic reticulum, 22 it may be that MPO protein synthesis does not proceed to completion, and our monoclonal antibody is detecting a proenzyme form of MPO. Discrepancies between these three methods have been previously reported. 8, 9 While there are scant data on the significance of the flow cytometric patterns of MPO expression, it is notable that all nine cases of relapse in our B-ALL-isoMPO group showed a variable tailed expression pattern at diagnosis. MPO expression in nonmalignant human cells is restricted to the myeloid lineage.
22 MPO expression in both adult and pediatric acute lymphoblastic leukemia has been noted for over 20 years by a number of independent investigators. [13] [14] [15] [16] [17] Arber et al 16 measured MPO expression by IHC in adult acute lymphoblastic leukemia with a polyclonal MPO antibody and found a high frequency of positive cases (23% of 82 cases). However, when a subset of these cases was assessed with a monoclonal antibody or by cytochemistry, they were negative. Western blotting with the polyclonal antibody detected the expected 55-kD band in both MPO-positive and MPO-negative adult B-ALL cases, suggesting that the polyclonal antibody was not specific and could erroneously lead to a diagnosis of MPAL. Our study exclusively used a monoclonal antibody, with the same clone throughout the study period. In a study of infant acute lymphoblastic leukemia (where diagnosis is made in the first year of life), MPO RNA expression was detected in 29 (56%) of 51 tested cases. 15 There was no correlation between expression of MPO RNA and clinical outcome in this cohort of patients.
18
Infant acute lymphoblastic leukemia is known to be associated with MLL rearrangements and an increased incidence of MPAL, and it is a well-established high-risk leukemia with a poor prognosis. We had no cases of infant ALL in any of our cohorts. Others have evaluated MPO RNA expression in cases of B-ALL and T-cell ALL (T-ALL). A study that included pediatric patients found that 44% of the acute lymphoblastic leukemia cases expressed MPO RNA. 17 MPO RNA was detected more frequently in older male patients, and there were associations with BCR-ABL rearrangements and other myeloid antigen expression. However, this group did not correlate MPO messenger RNA expression in acute lymphoblastic leukemia with patient outcomes. MPO has been detected in B-and T-ALL by electron microscopy as well. 19 Taken together, the enzyme, RNA, protein, and Univariate analysis of EFS shows no significant difference in patients with isolated myeloperoxidase expression in otherwise immunophenotypically standard B-cell acute lymphoblastic leukemia. *Log-rank P ¼ .6383. MPAL, mixedphenotype acute leukemia. ultrastructural data all suggest that MPO expression is indeed a feature of some cases of acute lymphoblastic leukemia. Most recently, a B-ALL gene expression profiling study examined high-risk pediatric B-precursor acute lymphoblastic leukemia cases and identified eight unique cluster groups. 20 One of the cluster groups was defined by high MPO RNA expression. They observed that patients in this group had a high rate of relapse (58.2% 6 16.9% four-year relapse-free survival), was heavily male skewed (10/11), was older (median, 14.2 years), and had zero incidence of MLL rearrangements. These patient cohort characteristics were very similar to our B-ALL-isoMPO patient cohort, supporting our conclusion that this patient cohort may be a high-risk cohort with distinct biological characteristics.
High-risk pediatric B-ALL is traditionally defined by a combination of clinical (age, WBC count) and laboratory (end induction minimal residual disease, specific genetic lesions) data. However, there are still significant genetic and outcome differences within these subsets of pediatric leukemias, and better classification of subtypes will improve allocation into appropriate risk-stratified treatment regimens in clinical trials and personalized treatments.
Our study provides the first published data on outcomes in pediatric patients with isolated MPO expression in otherwise typical B-ALL and suggests that these cases represent a high-risk leukemia, which are best classified as MPAL. If MPO is not measured in every case of leukemia by flow cytometry, patients may be at risk of undertreatment if diagnosed as having SR B-ALL.
